Delivery Order SPE2DB22D1017-SPE2DB24FF8XC

Award Date 6/4/24
Potential Completion Date 6/5/24
Potential Value $2.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,120.26 firm-fixed-price delivery order is for the supply of ZORYVE 0.3% Foam, a medical product, with a period of performance through October 2024. The contract is not designated under any set-aside program. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,781.33 firm fixed-price delivery order is for the supply of 4567585489 ! ZORYVE 0.3% FOAM 60GM medical products, with a period of performance through March 17, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ZORYVE 0.3% Foam, a medical product, with a ceiling value of $1,158.98 and an ultimate completion date of March 18, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop...
This federal contract award, valued at $2,988.77, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ZORYVE 0.3% FOAM 60GM, a topical medication, and does not have a set-aside designation. Amerisourcebergen holds an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999, which serves as a primary...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,131.87, is a Delivery Order with a Firm Fixed Price pricing type. It is for the supply of "ZORYVE 0.3% FOAM 60GM" medical products, with an ultimate completion date of March 14, 2025. The award is not designated as a set-aside contract. Amerisourcebergen holds a significant Indefinite...
This federal contract award from the Defense Logistics Agency (DLA) is a Delivery Order valued at $2,808.76 with a firm fixed price. The award went to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, to deliver Zoryve 0.3% Cream 60GM. This contract is not designated as a set-aside. The award is part of Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Zoryve 0.3% foam, a pharmaceutical product. The contract has a firm fixed price of $1,017.75 and a completion date of March 17, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,455.43 firm fixed-price delivery order is for ZORYVE 0.3% Cream, a pharmaceutical product, with a period of performance through January 24, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award, valued at $2,361.57, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a firm fixed-price delivery order with no set-aside designation, meaning it was open to full and open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
The federal contract award is for $20,362.44 and was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order with no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026....
  • SPE2DB22D1017
    Indefinite Delivery Contract
  • SPE2DB22D1017-SPE2DB24FF8XC
    Delivery Order

This federal contract award, valued at $2,281.63, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ZORYVE 0.3% FOAM 60GM, a medical product, with a completion date of June 5, 2024.

Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

The contract award did not have a set-aside designation, indicating open competition.

Generated 5/16/25, 12:22 PM